regulatory
Qlife Holding AB (“Qlife” or the “Company”) announced on 29 January 2025 that it had entered into an agreement for a credit facility of up to SEK 5.60 million (the “Credit Facility”) with JEQ Capital…
regulatory
The Transaction in short
Qlife and Hipro have collaborated since 2023 and have now entered a Letter of Intent to join forces through a reverse takeover.
Hipro's shareholders will hold…
regulatory
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Income statements and balance sheets…
regulatory
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary – first quarter 2025
Revenue in the period amounted to kSEK…
regulatory
The Annual Report can be downloaded from the website or ordered from Qlife, info@egoo.health.
For further information, please contact:
Thomas Warthoe, CEO Qlife Holding
Email: tw@egoo.health…
regulatory
Rätt att delta och anmälan
Den som önskar delta i stämman ska:
dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende fö…
not
regulatory
Qlife is a first mover in the growing market for at-home, lab-grade biomarker testing. The company’s strategic roadmap focuses on the following areas:
Hospital-at-Home - China market
Egoo Phe…
not
regulatory
The clinical trial will run for six months in the UK, after which the dossier will be submitted to the relevant UK authorities. As self-testing by non-professional users represents the highest…
regulatory
Election and remuneration of the board of directors
The extraordinary general meeting resolved to re-elect Lars Staal Wegner and Mikael Persson as ordinary board members and to elect Flemming…
regulatory
The rights issue that was announced on 29 January 2025 (the “Rights Issue”) in Qlife Holding AB (publ) (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office (…
regulatory
Qlife Holding AB (publ) (“Qlife” or the “Company”) has completed the issue of shares with preferential rights for the Company's shareholders that was resolved by the Board of Directors on 29 …
not
regulatory
With approximately 91 percent subscription in the rights issue and a secured credit facility, Qlife has ensured financing for at least the next 12 months. The company is now able to solely focus on…
regulatory
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Notification etc.
Anyone wishing…
regulatory
On 29 January 2025, Qlife Holding AB (“Qlife” or the “Company”) announced a rights issue of approximately SEK 11.8 million (the “Rights Issue”). The subscription period of the Rights Issue ended on…
regulatory
Tuesday, 25 February 2025, is the last day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) rights issue of approximately SEK 11.8 million (the “Rights Issue”). Please note…
not
regulatory
On 28 January 2025, Qlife signed a Letter of Intent (LOI) with a top-20 global pharmaceutical company to explore potential commercial collaborations. Among the key criteria outlined in the LOI was…
not
regulatory
The newly introduced Women’s Health product covers key aspects of fertility, menopause, thyroid disease and Vitamin D, enabling users to track and understand hormonal changes that impact their…
regulatory
The newly added biomarkers for Thyroid Disease and Vitamin D will be launched on the recently announced CE-IVD-marked platform, developed in collaboration with Hipro Biotechnology. With the addition…
regulatory
The non-binding intention from the Board of Directors and management amounts to approximately 1.2 MSEK. In addition, Lars Bangsgaard is also participating in the top-down-guarantee that was…
regulatory
Today, 11 February 2025, is the first day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) issue of a maximum of 5,883,817 shares with preferential rights for existing…
regulatory
The Board of Directors of Qlife Holding AB (“Qlife” or the “Company”) has, in connection with the Company's upcoming rights issue that was announced on 29 January 2025 (the “Rights Issue”), prepared…
regulatory
Financial summary – fourth quarter 2024
Revenue in the period amounted to kSEK 50 (30).
EBITDA for the period amounted to kSEK –7,721 (-86,903), and net loss kSEK – 7,106 (-111,545).…
regulatory
The sanction relates to an incident in February 2023 when Thomas Warthoe forwarded an email with details related to a rights issue. The e-mail was forwarded to Peter Warthoe, CSO of the company and…
regulatory
Today, the Board of Directors in Qlife Holding AB (“Qlife” or the “Company”) has, with the authorisation granted from the annual general meeting held on 26 June 2024, resolved to carry out an issue…
regulatory
Qlife is actively pursuing a partnership strategy and, with recent advancements in the Egoo Health product lines, expects to establish one or more partnerships during 2025. These collaborations will…
regulatory
Qlife and Hipro Biotechnology have joined forces to introduce a jointly developed, CE-IVD-marked platform to the market. This new solution combines the best of Hipro’s technology with Egoo Health’s…
not
regulatory
The company has shifted its focus from research and development to becoming a sales-driven organization, emphasizing the distribution of its high-quality Egoo Health product platform in the rapidly…
not
regulatory
Since the summer, Qlife has been working diligently in close collaboration with its partner, Hipro Biotechnology, in China. The company is pleased to share the following updates:
Excellent…
regulatory
The exercise period for warrants of series TO 5 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue of units in February 2024 (the "Rights Issue") begins…
regulatory
Qlife har informerats om att Stefan Kylebäck kommer att efterträdas av Mattias Olofson som således kommer blir ny huvudansvarig revisor för Qlife. Bytet sker omgående.
För ytterligare…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTH KOREA…
regulatory
Resolution on whether the company shall enter into liquidation or continue its operations
It was noted that the second control balance sheet shows that the company's total equity is fully restored.…
regulatory
Financial summary – third quarter 2024
Revenue in the period amounted to kSEK 0 (45).
EBITDA for the period amounted to kSEK –27,151 (-6,660), and net loss kSEK – 28,087 (-8,926).
The total…
regulatory
Rätt att delta och anmälan
Den som önskar delta i stämman ska:
dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som…
regulatory
On 29 August 2024, Qlife announced its intention to change the Company’s name to Egoo Health AB as part of a broader rebranding initiative. However, the Swedish Companies Registration Office has…
not
regulatory
An at-home PHE test will significantly improve the quality of life for people with Phenylketonuria. Qlife's regulatory strategy involves releasing the product as a CE-RUO test, backed by sufficient…
regulatory
An at-home PHE test will significantly improve the quality of life for people with Phenylketonuria. Qlife's regulatory strategy involves releasing the product as a CE-RUO test, backed by sufficient…
regulatory
Peter Warthoe is one of the co-founders of Qlife but decided a few years ago to step out of the management role to focus more on his scientific projects. Given the company’s new lean structure and…
regulatory
On 21 March 2024, the Company presented a balance sheet for liquidation purposes, showing that the equity was less than half of the registered share capital. On 28 March 2024, Qlife announced that…
not
regulatory
The Company reports that, in collaboration with its partner Hipro, progress has been made on the four key objectives set for their partnership. The integration and validation of Hipro biochemistry…
not
regulatory
As outlined in the press release dated 29 August 2024, Qlife has successfully executed directed issues of shares and warrants pursuant to the authority granted by the annual general meeting 2024.…
regulatory
Qlife Holding AB (publ) (“Qlife” or the “Company”) announces the acquisition of the assets of the Company's subsidiary Qlife ApS in bankruptcy, including goodwill and…
regulatory
Financial summary – second quarter 2024
Revenue in the period amounted to kSEK 39 (46).
EBITDA for the period amounted to kSEK –8,002 (-16,287), and net loss kSEK –12,979 (-22,703).
The total…
regulatory
Årsstämman i Qlife beslutade den 26 juni 2024 om sammanläggning av aktier 1:2000, innebärande att 2000 befintliga aktier läggs samman till 1 aktie. Styrelsen i Qlife fastställde avstämningsdagen för…
regulatory
Today, the reconstructor, has concluded that there is no viable path to secure financing for Qlife’s subsidiary, Qlife ApS. Consequently, the board of directors has decided to declare…
regulatory
Sammanläggning av aktier
Årsstämman beslutade den 26 juni 2024 om sammanläggning av aktier varigenom tvåtusen (2 000) befintliga aktier läggs samman till en (1) aktie. För att möjliggöra…
not
regulatory
For a couple of weeks during June Qlife was invited to participate Emory’s Metabolic Camp and run a research trial with the aim of making a comparison study of blood data on Egoo compared to data…
regulatory
Qlife Holding AB höll den 26 juni 2024 årsstämma varvid i huvudsak följande beslut fattades.
Fastställande av räkenskaper samt resultatdisposition
Årsstämman beslutade att fastställa resultat- och…
regulatory
On 13 March 2023, Qlife Holding AB (“Qlife” or the “Company”) announced that Aidian Oy had initiated arbitration proceedings against Qlife’s wholly owned subsidiary Qlife ApS regarding payment of…
regulatory
Qlife Holding AB (“Qlife” or the “Company”) and Atlas Special Opportunities, LLC (“Atlas”), have entered into a non-binding term sheet on 13 May 2024. According to the term sheet, Atlas will fund the…
regulatory
Terms for warrants series TO 4 in brief:
The exercise price is SEK 0.02 per share.
The exercise period runs from 7 – 21 June 2024.
Each warrant entitles the holder to subscribe for one (1) share…
regulatory
The annual report can be downloaded from the website or ordered from Qlife, info@egoo.health.
For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
Certified…
regulatory
Since last year, Qlife has worked diligently towards transferring the Egoo Health platform to Hipro in China to setup pilot production of consumables, validate performance with Hipro reagents, and…
regulatory
Financial summary – first quarter 2024
Revenue in the period amounted to kSEK 0 (123). No revenue of Egoo.Health devices and capsules for the device.
EBITDA for the period amounted to kSEK –11,…
regulatory
Rätt att delta och anmälan
Den som önskar delta i stämman ska:
dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som…
regulatory
On 3 August 2024, the board of directors of the Company resolved on a directed issue of convertible debentures, with a total owed amount before interest of SEK 7,745,058 (including the set-up fee).…
regulatory
Resolution on whether the company shall enter into liquidation or continue its operations
The extraordinary general meeting resolved in accordance with the primary proposal from the board of…
regulatory
“Qlife is following our operational plans, but since we have a called for an extraordinary general meeting later this month to resolve on the company’s balance sheet, we have chosen at the same time…
regulatory
“Qlife is following our operational plans, but since we have a called for an extraordinary general meeting later this month to resolve on the company’s balance sheet, we have chosen at the same time…
regulatory
The rights issue of units that was announced on 12 December 2023 (the “Rights Issue”) in Qlife Holding AB (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office…
not
regulatory
It has been mentioned in the media that Qlife is no longer focused on the EU and other markets. However, as communicated previously, Qlife is focused on finalizing regulatory work in China and roll-…
regulatory
Qlife is pleased to announce that it has signed a Letter of Intent (LOI) with leading South Korean company Precision Biosensor, to introduce Egoo Health to the South Korean market. Qlife anticipates…
regulatory
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
The shareholders of Qlife Holding AB…
not
regulatory
Qlife has today called for an EGM because it is obliged to do so when the company has written down half of its equity as previously communicated in connection with the company’s year-end report for…
regulatory
As communicated in the Company’s year-end report for the financial year 2023, the board of directors of Qlife has, in accordance with Chapter 25, Section 13 of the Swedish Companies Act, prepared a…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
not
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
not
regulatory
The key feature of the innovation is the ability to perform analysis in a microenvironment with fixed alignment, so no variability is seen between analysis and readout.
“This core patent protects…
not
regulatory
The collaboration consists of four major parts:
Integration of reagents
Regulatory approval in China
Distribution and sales in China
Production of Egoo in China
Integration of reagents
The…
not
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
regulatory
Financial summary – fourth quarter 2023
Revenue in the period amounted to kSEK 30 (1,097). Revenue includes sales of Egoo.Health devices and capsules for the device. Revenue in Q4 is…
regulatory
Financial summary – fourth quarter 2023
Revenue in the period amounted to kSEK 30 (1,097). Revenue includes sales of Egoo.Health devices and capsules for the device. Revenue in Q4 is solely from…
regulatory
The postponement is due to administrative reasons.This information was submitted for publication, through the agency of the contact person set out above, on 04-02-2024 21:53 CET.
regulatory
Resolution on (A) amendment of the Articles of Association; and (B) reduction of the share capital without redemption of shares
The extraordinary general meeting resolved in accordance with the…
regulatory
Right to participate and notification
Shareholders wishing to participate in the meeting must:
partly be listed in the company’s share register kept by Euroclear Sweden AB as of Monday 8 January…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
not
regulatory
Qlife has on Monday 4th of December entered into a final collaboration agreement with Hipro Biotechnology. The parties will from now on work diligently towards achieving market clearance for Egoo…
not
regulatory
The agreement in brief
The agreement consists of four major parts:
Integration of reagents
Regulatory approval from the China Food and Drug Administration for Egoo Health
Distribution and sales…
regulatory
Peter Thorsen is a Certified Public Accountant (CPA) with an impressive background in finance, having previously served in key roles at prominent organizations such as EY, DSV A/S, Domea, Widex A/S,…
regulatory
Financial summary – third quarter 2023
• Revenue in the period amounted to kSEK 45 (1,967). Revenue includes sales of Egoo.
Health devices and capsules for the device. Revenue in Q3 is…
regulatory
In total, Qlife issued 622,348,940 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 3. One (1) warrant entitled the right to subscribe for one (1) new share…
regulatory
The technology and overall strategy
Qlife has invested more than SEK 300 million in the development of Egoo Health, a unique biomarker self-testing system for measuring and monitoring blood data…
regulatory
Terms for warrants series TO 3 in brief:
The exercise price is SEK 0.11 per share.
The exercise period runs from 11 – 29 September 2023.
Each warrant entitles the holder to…
regulatory
Financial summary – second quarter 2023
In Q2 2023 QLife has completed restructuring of its operation by reducing the number of employees and terminating a long term lease for…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
regulatory
Pursuant to Qlife’s articles of association, the board of directors shall be comprised of not less than three and not more than eight board members. After Mette-Marie Harild’s resignation, the board…
not
regulatory
The open system provides the opportunity of innovating and implementing proprietary biomarker assay projects on to the at-home diagnostic system. Now, researchers can join the quest to broaden access…
regulatory
In total, Qlife issued 2,884,980 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 2. One (1) warrant entitled the right to subscribe for 1.08 new shares in…
not
regulatory
Since the start of 2023, Qlife has continuously scaled down on costs, workforce and operates mainly by outsourcing. The termination of the lease is part of Qlife’s new operation model to implement…
not
regulatory
“Since the IPO in March 2020 Qlife has achieved a lot of encouraging goals”, says CEO Thomas Warthoe. “We have continuously listened to the market to adjust our offers and have now concluded that we…
regulatory
Terms for warrants series TO 2 in brief:
The exercise price has been set to SEK 0.21 per share. The exercise price has been defined as seventy (70) per cent of the volume-weighted average price…
regulatory
The rights issue of units that was announced on 16 February 2023 (the “Rights Issue”) in Qlife Holding AB (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office…
regulatory
Financial summary – first quarter 2023
Revenue in the period amounted to kSEK 123 (10,905). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test…
regulatory
On 4 May 2023, the annual general meeting was held in Qlife Holding AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.
Resolution on…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
regulatory
Subscription and allotment
The subscription summary shows that 122,853,750 units, corresponding to approximately 21.3 percent of the Rights Issue, were subscribed for by exercise of unit rights. In…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
regulatory
The full report is available in English at the following url.:
https://qlifeholding.com/en/investors/finansiella-rapporter
Qlife has changed to English as the sole language for market…
regulatory
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Right to participate and…
regulatory
Qlife’s Nomination Committee proposes that the Annual General Meeting elects Lars Bangsgaard as new Chairman of the Board, Lars Wegner as new Board member and re-election of Mette-Marie Harild,…
regulatory
Resolution on amendment of the Articles of Association
The extraordinary general meeting resolved in accordance with the proposal from the board of directors to amend the provisions in the Articles…
not
regulatory
In 2020, Qlife entered into a cooperation with the Finnish company Aidian Oy. Several agreements between the parties were concluded in 2020 and 2021, according to which Qlife undertook to purchase…
regulatory
Right to participate and notification
Shareholders wishing to participate in the meeting must:
partly be listed in the company’s share register kept by Euroclear Sweden AB as of Thursday 16…
regulatory
Summary of the Rights Issue
The Rights Issue is proposed to be carried out on the following main terms:
The Rights Issue comprises a maximum of 576,813,400 units, corresponding to a maximum of…
regulatory
Financial summary – fourth quarter 2022
Revenue in the period amounted to kSEK 1,097 (12,084). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test…
regulatory
Financial summary – fourth quarter 2022
Revenue in the period amounted to kSEK 1,097 (12,084). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test…
not
regulatory
“With this launch, Qlife really can start delivering on our vision of bringing lifestyle biomarker testing with quantitative precise data to a wider health-conscious audience and for home use”, says…
not
regulatory
With the launch of our CRP capsule, Qlife will start delivering on our vision of bringing lifestyle biomarker testing with quantitative precise data to a wider health conscious audience and for home…
not
regulatory
Qlife has been able to develop a small, freeze-dried bead that consist of the CRP reagents used in the Egoo CRP Capsule. Instantly frozen reagents which then are freeze-dried into spherical beads are…
regulatory
Financial summary – third quarter 2022
Revenue in the period amounted to kSEK 1,967 (5,871). Revenue includes sales ofEgoo.Health devices and capsules for the device. Continued…
not
regulatory
In December 2021, Qlife signed an agreement with FIND for $ 3.45 million for a 12-month project with the goal of developing a new and cost-effective two-in-one test for influenza and SARS-CoV-2 virus…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
not
regulatory
The Nomination Committee consists of the following persons, who together represent approximately 24 percent of the company's shares and votes.
Anita Otterheim Hjalmarsson, appointed by Thomas…
regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH…
not
regulatory
This is the largest biohacker event in the world and gathers people, companies, and organizations across the medical, health, and wellbeing sector, providing an optimal platform for networking,…
regulatory
Publication of Prospectus
The Prospectus has been prepared in connection with the Rights Issue and has today, 30 September 2022, been approved and registered by the Swedish Financial Supervisory…
regulatory
During the past year, Qlife has been transitioning and transforming to a post-covid reality. The current cost reductions are related to a significantly reduced demand for covid-tests and primarily…
regulatory
Resolution on amendment of the Articles of Association
The extraordinary general meeting resolved in accordance with the proposal from the board of directors to amend the provisions in the Articles…
not
regulatory
September 26 at Stora Aktiedagen in Lund
Venue: Elite Hotel Ideon
Time: 08.30-09.00
The presentation will be held in English and the event is open to the public, as well as live-streamed and…
regulatory
FINANCIAL SUMMARY – SECOND QUARTER 2022
Revenue in the period amounted to kSEK 4,025 (10.482). Revenue includes sales of Egoo.Health devices and capsules for the device. The decline in…
regulatory
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Right to participate and…
regulatory
Investor meeting due to the Rights Issue
In connection with the Rights Issue, current shareholders and others are invited to a digital presentation and Q&A with CEO Thomas Warthoe and CFO Kasper…
not
regulatory
Qlife updates vision and websites – Reinforced emphasis on making Egoo Health available for home use
Qlife was founded based on the idea that Egoo Health could help people lead a better life by using the diagnostics self-testing platform Egoo Health. Today, the short-term focus is on completing…
not
regulatory
“The new agreement with Scanfil is a milestone for Qlife. As part of our long-term strategy, we initiated the outsourcing a while ago, and we expect the cooperation to give us both a better…
not
regulatory
The National PKU Alliance (NPKUA) is the largest event for the PKU community in the world and brings together patients, relatives, industry, and research partners every two years. This year, Qlife…
regulatory
The loans are granted by Modelio Equity AB and a large private shareholder in Qlife. The loan term runs over six months from June to December 2022. The loans are entered into on market terms of 1.5%…
not
regulatory
In December 2021, Qlife signed an agreement with FIND for $ 3.45 million for a 12-month project with the goal of developing a new and cost-effective two-in-one test for influenza and SARS-CoV-2 virus…
not
regulatory
By meeting regularly Qlife’s new Scientific Advisory Board will offer insights into the latest development within the specific fields of Molecular Diagnostics. The engagement of the members of the…
regulatory
Qlife’s scientific team has completed the development of a blood-to-plasma filtration unit for blood-based biomarker testing. The Egoo capsule already integrates all reagents and with the new…
regulatory
Resolution on adoption of accounts and distribution of the company’s result
The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income…
regulatory
FINANCIAL SUMMARY – FIRST QUARTER 2022
Revenue in the period amounted to kSEK 10,905 (11,176). Revenue includes sales of Egoo.Health devices and capsules for the device. We saw strong sales…
regulatory
Qlife Holding AB’s Annual report 2021 is from today available in swedish and english on the company’s website, www.qlifeholding.com.
https://qlifeholding.com/sv/investerare/finansiella-…
regulatory
Right to participate and notification
Shareholders wishing to participate in the annual general meeting must:
partly be listed in the company’s share register kept by Euroclear Sweden AB as of…
not
regulatory
The study set-up was using Hvidovre Hospital best practice for covid-19 testing (RT-qPCR) as the comparator method. Thus, the test execution deviates from the Egoo.Health Intended Use and Instruction…
not
regulatory
"We are surprised that the results from the Danish clinical evaluation differ from previously scientific and published study on more than 1000 samples, which among others were conducted together…
regulatory
FINANCIAL SUMMARY – FOURTH QUARTER 2021
Revenue in the period amounted to kSEK 12,084 (9,122). Revenue regards sales of Egoo.Health devices and COVID-19 test capsules.
EBITDA for the period…
regulatory
Qlife has signed an agreement with FIND, the global alliance for diagnostics, for an funding of 3,45 MUSD for a 12-month project to develop a novel two-in-one assay for the detection of influenza and…
regulatory
Kasper Rousøe has more than 20 years of experience from leading roles in the financial area, most recently from Phase One A/S. He has previously been CFO and Finance Director in Bauer Media Group,…
regulatory
FINANCIAL SUMMARY – THIRD QUARTER 2021
Revenue in the period amounted to kSEK 5,871 (5,062). Sales regards COVID-19 tests from the test service center as well as Egoo.Health devices and capsules…
not
regulatory
Today, most people get their diagnosis through so-called quantitative polymerase chain reaction (qRT-PCR) which is performed in specialized laboratories. This means that it often takes more than 24…
not
regulatory
In accordance with the decision at Qlife Holding's Annual General Meeting 2021, the company's Chairman of the Board has convened a Nomination Committee to prepare proposals for the Company's Annual…
not
regulatory
Wednesday, December 1 at Stora Aktiedagen in Stockholm
Time: 12.00-12.30
Thursday 2 December at Västra Hamnen in Malmö
Time: TBD
Investors, analysts and the media need to sign up for each event.…
regulatory
“It has been a fantastic journey that I am proud to have been a part of. My expertise is primarily to assist companies in the start-up phase, and that is really not Qlife anymore, and therefore it is…
regulatory
FINANCIAL SUMMARY – SECOND QUARTER 2021
Revenue in the period amounted to kSEK 10,482 (6,181). Sales regards COVID-19 tests from the test service center as well as Egoo.Health devices and capsules…
not
regulatory
Today, most people get their diagnosis through so-called quantitative polymerase chain reaction (qRT-PCR) which is performed in specialized laboratories. This means that it often takes more than 24…
not
regulatory
In connection with the European Football Championship in Copenhagen in the coming weeks, Qlife is expanding its testing capacity for Covid-19 to give more people access to RT-PCR tests with…
not
regulatory
The division means that Thomas Warthoe’s, Peter Warthoe’s and Lars Bangsgaard's respective companies have acquired 1,201,200 shares each from PKV Consult IVS, and Ebbe Finding is now the sole owner…
regulatory
The exercise period for the warrants of series TO 1 took place from May 3, 2021 up to and including May 31, 2021. The subscription price per share for the exercise of warrants of series TO 1 amounted…
regulatory
At the Annual General Meeting on May 5, 2021, an incentive program aimed at three new board members of the company was resolved. The warrant terms are based on a market valuation according to…
not
regulatory
The warrant holders have the right to subscribe for one (1) new share in Qlife for each two (2) owned warrants of series TO1 at a price of SEK 17.50 per share. The number of warrants of series TO1…
regulatory
Resolution on adoption of accounts and allocation of the company’s result
The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income…
regulatory
FINANCIAL SUMMARY - FIRST QUARTER 2021
Revenue in the period amounted to kSEK 11,176 (385). Revenue regards sales of COVID-19 tests from the test service center as well as Egoo.Health devices and…
not
regulatory
The subscription period runs from 3 May 2021 until 31 May 2021. Two (2) warrants entitle to subscription of one (1) new share in the Company at a price of SEK 17.50 per share. If all warrants are…
regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE “UNITED STATES”), AUSTRALIA, CANADA, HONG KONG,…
not
regulatory
Qlife invites investors, financial analysts and the media to a presentation where Thowas Warthoe will comment on the report. The report will be released at 08:…
regulatory
Qlife has been part of a development programme at the oncology department at Herlev Hospital since 2018, intended to validate home monitoring of kidney cancer patients. The project has been delayed…
regulatory
The agreement covers a range of European countries, including Sweden, Norway, Finland, Germany, Netherlands, Belgium, Luxembourg, Austria, Switzerland, Poland, Czech Republic, Hungary, Slovakia,…
regulatory
The report can be downloaded from the website or ordered via the company; info@Egoo.health.This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the Swedish…
regulatory
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
The shareholders of Qlife Holding AB…
regulatory
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
In light of the ongoing Covid-19…
regulatory
Qlife’s Nomination Committee proposes that the Annual General Meeting elects Mette-Marie Harild, Ulrik Harrysson and Mikael Persson as new Board members.
Mette-Marie Harild, born 1958, has a long…
regulatory
FINANCIAL SUMMARY - FOURTH QUARTER 2020
Revenue in the period amounted to kSEK 9,122 (0). Sales regards COVID-19 test capacity to customers mainly within sports, through the partner KMD.
EBITDA…
not
regulatory
“It is of great importance for Qlife to get a significant order from a highly professional customer directly after the CE-marking. It manifests the demand for tests of laboratory quality combined…
not
regulatory
The Danish Patent Office has granted Qlife patent number DK180348 B1 for its biomarker detection unit. The biomarker detection unit consist of an integrated optical microelectromechanical system (…
not
regulatory
The current CE-mark applies to the professional use of the test platform Egoo.Health for sale on the European market. The next step is to place the COVID-19 test in strategic locations, where it can…
regulatory
Qlife expects to CE mark its COVID-19 test for professional use in the Egoo.Health system within short. With the CE mark, Qlife's cost-effective, fast, and mobile PCR tests can be marketed and sold…
not
regulatory
Since May 2020, Qlife has been handling all testing for COVID-19 for professional football in Denmark. The test capacity includes weekly testing of all players and staff in league clubs in order to…
not
regulatory
On November 13, Qlife was informed that the Danish Medicines Agency (Lægemiddelstyrelsen) had rejected the application for temporay approval in Denmark “in the interest of health protection” for the…
not
regulatory
”We will do our utmost to protect the participating players against the coronavirus”, says Frank Smith, Covid-19 Officer, European Handball Federation Euro 2020 “It requires testing with high…
regulatory
Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants
The meeting resolved in accordance with the proposal from the board of directors to…
regulatory
FINANCIAL SUMMARY - THIRD QUARTER 2020
Revenue in the period amounted to kSEK 5,062 (714). Sales regards COVID-19 test capacity to customers mainly within sports, through the partner KMD.
EBITDA…
regulatory
In parallel to the ongoing process of preparing and putting together the dossier for the CE-mark, Qlife has submitted an application for placing the product on the market at this stage, as it offers…
not
regulatory
The Nomination Committee consists of the following persons, who together represent approximately 39 percent of the company's shares and votes.
Sören Skjärbäk, appointed by PKV Consult IVS,
Sören…
regulatory
Information regarding the coronavirus
As a precautionary measure to reduce the risk of spreading the coronavirus, the board of directors of Qlife Holding AB (”Qlife”) has decided to keep planned…
regulatory
Qlife was originally expecting CE-mark for the product in October, but the company is now expecting approval within the coming two to three months. In the mean time, Qlife has submitted an…
not
regulatory
Due to the increasing of infectious rates over the past few weeks, it has been agreed that Qlife will be handling all testing for COVID-19 for professional handball in Denmark. Testing will start…
regulatory
FINANCIAL SUMMARY – SECOND QUARTER 2020
Revenue in the period amounted to kSEK 6,181 (0) and is mainly related to sales to KMD regarding the agreement with Danish Football League to test players…
not
regulatory
In cooperation with KMD, Qlife has extended the contract with Divisionsforeningen. The extended contract is the continuation of COVID-19 testing of players and personnel in the two best football…
not
regulatory
Qlife's focus on professional sports is centered around COVID-19 testing, which the company offers in collaboration with IT partner KMD. COVID-19 testing contracts have been closed with various…
regulatory
Jakob has extensive experience from international sales and business development within MedTech and healthcare and brings an excellent record of results and achievements in complex and competitive…
not
regulatory
In April we closed a contract with the professional Danish football league for regular testing of all players and staff for COVID-19 and delivery of test results were initiated already in week 22.…
regulatory
"Henrik Ljung brings broad experience to Qlife from financial reporting, IR, business control, finance management and corporate governance, all with a focus on fast-growing companies in the early…
not
regulatory
KMD and Qlife has entered an agreement with Badminton Denmark to COVID-19 test all players in the final game of the Danish badminton tournament for clubs, RSL Final 4.
"The fact that we COVID-19…
not
regulatory
Geelmuyden Kiese and KMD announced earlier today that they have entered a partnership to provide smart and efficient Covid-19 test solutions for the professional sports, culture, and entertainment…
not
regulatory
The first phase of developing the antibody test will be outsourced to an existing partner and is expected to take approximately three months. Thereafter, the project will be transferred to in-house…
regulatory
Resolution on adoption of accounts and allocation of the company’s result
The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income…
regulatory
FINANCIAL SUMMARY FIRST QUARTER 2020
Revenue for the period amounted to kSEK 385 (0) and regards a collaboration project with a Danish hospital.
EBITDA for the period amounted to kSEK -5,732 (-1,…
regulatory
The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga). The parties have developed a test protocol…
not
regulatory
Qlife announces that it has entered into a research agreement with Nordsjællands Hospital (NOH), to continue the validation of the Egoo Sars-CoV-2 virus test. The focus of the collaboration is to…
regulatory
Information regarding the coronavirus
As a precautionary measure to reduce the risk of spreading the coronavirus, the board of directors of Qlife Holding AB (”Qlife”) has decided to keep planned…
not
regulatory
Due to increased requests for information on route to market for Qlife’s COVID-19 test the company is updating the following:
After having finalized the licensing agreement to COVID-19…
regulatory
Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform. The companies have…
not
regulatory
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak. The interest…
not
regulatory
Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm. Qlife Holding AB (“Qlife”) belongs to…
not
regulatory
The short name for the Company’s shares on Nasdaq First North is QLIFE. The short name for the TO1 series warrants is QLIFE TO1.
Qlife has appointed G&W Fondkommission as certified advisor (…
not
regulatory
The Egoo Home System is an integrated platform consisting of a small device, disposable capsules, each a test for a specific biomarker, and a digital infrastructure that can share data with patient…
not
regulatory
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Stockholm on 25 November. Would you like to read more about the programme and how to sign up, see attached…
not
regulatory
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Gothenburg on 4 November and in Stockholm on 25 November. Would you like to read more about the programme and how to…
not
regulatory
The home diagnostic device from Danish start-up Qlife can make the lives of patients with chronic diseases easier. This is the way forward towards a more human centered public health sector, says one…
not
regulatory
Qlife is showcased by the Danish Minister of Health and the Minister for Industry, Business and Financial Affairs for the launch of new public program for innovative purchasing of medical equipment…
not
regulatory
In the enclosed Newsletter you will find updated information about our operations and preparations for next steps.
not
regulatory
Biomarkers in our blood can show us a lot about our health, the development of a disease or how tough we have been to our body during a workout. Up until now, these bio markers could only be measured…
not
regulatory
Every day, the Danish healthcare system produces a large amount of data. In the future, new data sources, such as data from patients, personal health tools and apps, will substantially…
not
regulatory
Six interesting companies in total will present their businesses.
Watch the video of the presentation